Post-polycythemia vera myelofibrosis
Drug research and approvals for post-polycythemia vera myelofibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 20 studies of post-polycythemia vera myelofibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891 · Phase 1 · Prelude Therapeutics Incorporated · starts Apr 29, 2026
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNCT07447817 · Phase 2 · John Mascarenhas · starts Oct 23, 2026
- Therapeutic RSK1 Targeting in Myeloid MalignanciesNCT07379125 · Phase 1 · Washington University School of Medicine · starts May 20, 2026
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With…NCT07362225 · Not reported · MPN Research Foundation · starts Sep 26, 2025
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727 · Phase 3 · Novartis Pharmaceuticals · starts May 27, 2026
- Research Platform Myelofibrosis and AnemiaNCT06976918 · Not reported · iOMEDICO AG · starts Feb 19, 2026
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisNCT06517875 · Phase 2 · GlaxoSmithKline · starts Feb 28, 2025
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal…NCT06479135 · Phase 3 · Kartos Therapeutics, Inc. · starts Jun 3, 2024
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)NCT06351631 · Phase 3 · Merck Sharp & Dohme LLC · starts May 23, 2024
| Nov 29, 2019 | A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…Pacritinib (SB1518) / Ruxolitinib / Hydroxyurea / Danazol | Sobi | Ongoing |
| Nov 13, 2019 | A randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in symptomatic, anemic subjects with primary…Momelotinib (MMB) / Danazol | Sierra Oncology | Ongoing |
| Feb 28, 2018 | Extended access of momelotinib for subjects with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…Momelotinib | GSK | Closed |
| Jan 10, 2017 | A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.Jakavi (INC424, ruxolitinib) | Novartis Pharmaceuticals | Closed |
| May 9, 2014 | A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…Pacritinib (SB1518) | Cti Biopharma | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 16, 2011 | JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis… | Incyte Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA